Submit the keyword or topic you are searching for

  1. Home
  2. Business
  3. CLSA maintains 'high-conviction outperform' on NHPC shares, sees 44% upside
Business

CLSA maintains 'high-conviction outperform' on NHPC shares, sees 44% upside

featured-image

The correction in NHPC's stock can give investors an inexpensive opportunity to accumulate, noted brokerage CLSA..

My Protein Germany

Myprotein UK

Menkind UK

Top News

A Legacy Preserved: Grand Museum Commemorating Political Stalwarts

A Legacy Preserved: Grand Museum Commemorating Political Sta...

Citigroup Soars Amid Market Volatility

China Tells Airlines To Suspend Boeing Jet Deliveries: Report

Robert Vadra at ED office after fresh summons in Gurugram land deal case

Related Posts

post-thumbnail
Business

Lafayette Square Provides Financing to Support Maxwell Street Capital Partners' Investment in Port Jersey Logistics

post-thumbnail
Business

Instylla Announces the Appointment of Daniel Davis to Board of Directors

post-thumbnail
Business

5 Analysts Assess Autoliv: What You Need To Know

post-thumbnail
Business

The towering legacy of Dikembe Mutombo

post-thumbnail
Business

Deep Dive Into Visteon Stock: Analyst Perspectives (8 Ratings)

post-thumbnail
Business

Demystifying MaxLinear: Insights From 6 Analyst Reviews

post-thumbnail
Business

Healthcare AI Company Breaks Through Final Barrier for Automated Genome Interpretation

post-thumbnail
Business

Biocon Biologics Secures Market Entry Date for YesafiliTM, an Interchangeable Biosimilar to Eylea®, in the U.S.